Parent Pauline, Marcq Gautier, Adeleke Sola, Turpin Anthony, Boussios Stergios, Rassy Elie, Penel Nicolas
Medical Oncology Department, Centre Hospitalier Universitaire de Lille (CHU Lille), University of Lille, Hôpital Huriez, Lille 59037, France.
Urology Department, Claude Huriez Hospital, Centre Hospitalier Universitaire de Lille (CHU Lille), Lille, France.
Ther Adv Med Oncol. 2023 Sep 7;15:17588359231192402. doi: 10.1177/17588359231192402. eCollection 2023.
Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced urothelial cancer. However, a significant number of patients do not respond to ICI, and the lack of validated predictive biomarkers impedes the success of the ICI strategy alone or in combination with chemotherapy or targeted therapies. In addition, some patients experience potentially severe adverse events with limited clinical benefit. Therefore, identifying biomarkers of response to ICI is crucial to guide treatment decisions. The most evaluated biomarkers to date are programmed death ligand 1 expression, microsatellite instability/defective mismatch repair phenotype, and tumor mutational burden. Other emerging biomarkers, such as circulating tumor DNA and microbiota, require evaluation in clinical trials. This review aims to examine these biomarkers for ICI response in urothelial cancer and assess their analytical and clinical validation.
免疫检查点抑制剂（ICIs）常用于治疗晚期尿路上皮癌患者。然而，相当一部分患者对ICI无反应，且缺乏经过验证的预测性生物标志物阻碍了ICI单药治疗或与化疗或靶向治疗联合使用策略的成功。此外，一些患者经历了潜在的严重不良事件，临床获益有限。因此，识别对ICI反应的生物标志物对于指导治疗决策至关重要。迄今为止评估最多的生物标志物是程序性死亡配体1表达、微卫星不稳定性/错配修复缺陷表型和肿瘤突变负荷。其他新兴的生物标志物，如循环肿瘤DNA和微生物群，需要在临床试验中进行评估。本综述旨在研究这些用于尿路上皮癌ICI反应的生物标志物，并评估它们的分析和临床验证情况。
